메뉴 건너뛰기




Volumn 61, Issue 4, 2012, Pages 652-661

Risk-based prostate cancer screening

Author keywords

Early detection of cancer; Mass screening; Nomograms; Prostate neoplasms; Prostate specific antigen; Risk factors

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

EID: 84857642325     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.11.029     Document Type: Review
Times cited : (111)

References (114)
  • 2
    • 69249209651 scopus 로고    scopus 로고
    • Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)
    • M.J Roobol, M. Kerkhof, and F.H. Schröder Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 2009 584 591
    • (2009) Eur Urol , vol.56 , pp. 584-591
    • Roobol, M.J.1    Kerkhof, M.2    Schröder, F.H.3
  • 3
    • 63249118690 scopus 로고    scopus 로고
    • Screening and prostate-cancer mortality in a randomized European study
    • F.H. Schröder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
    • (2009) N Engl J Med , vol.360 , pp. 1320-1328
    • Schröder, F.H.1    Hugosson, J.2    Roobol, M.J.3
  • 4
    • 77955279420 scopus 로고    scopus 로고
    • Mortality results from the Goteborg randomised population-based prostate-cancer screening trial
    • J. Hugosson, S. Carlsson, and G. Aus Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
    • (2010) Lancet Oncol , vol.11 , pp. 725-732
    • Hugosson, J.1    Carlsson, S.2    Aus, G.3
  • 5
  • 7
    • 70350457793 scopus 로고    scopus 로고
    • A framework for the identification of men at increased risk for prostate cancer
    • M.J. Roobol, F.H. Schröder, and E.D. Crawford A framework for the identification of men at increased risk for prostate cancer J Urol 182 2009 2112 2120
    • (2009) J Urol , vol.182 , pp. 2112-2120
    • Roobol, M.J.1    Schröder, F.H.2    Crawford, E.D.3
  • 8
    • 70449525320 scopus 로고    scopus 로고
    • A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer
    • M.J. Roobol, E.W. Steyerberg, and R. Kranse A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer Eur Urol 57 2010 79 85
    • (2010) Eur Urol , vol.57 , pp. 79-85
    • Roobol, M.J.1    Steyerberg, E.W.2    Kranse, R.3
  • 9
    • 79959560114 scopus 로고    scopus 로고
    • Disease-specific survival of men with prostate cancer detected during the screening interval: Results of the European Randomized Study of Screening for Prostate Cancer-Rotterdam after 11 years of follow-up
    • X. Zhu, P.J. van Leeuwen, and M. Bul Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European Randomized Study of Screening for Prostate Cancer-Rotterdam after 11 years of follow-up Eur Urol 60 2011 330 336
    • (2011) Eur Urol , vol.60 , pp. 330-336
    • Zhu, X.1    Van Leeuwen, P.J.2    Bul, M.3
  • 11
    • 0030635849 scopus 로고    scopus 로고
    • Trends in prostate carcinoma incidence in Connecticut (1988-1994) by age and race
    • A.P. Polednak Trends in prostate carcinoma incidence in Connecticut (1988-1994) by age and race Cancer 79 1997 99 103
    • (1997) Cancer , vol.79 , pp. 99-103
    • Polednak, A.P.1
  • 12
    • 0027937517 scopus 로고
    • High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases
    • W.A. Sakr, D.J. Grignon, and J.D. Crissman High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases In Vivo 8 1994 439 443
    • (1994) In Vivo , vol.8 , pp. 439-443
    • Sakr, W.A.1    Grignon, D.J.2    Crissman, J.D.3
  • 13
    • 0023191075 scopus 로고
    • Cancer of the prostate: Epidemiology and aetiology
    • D.G. Zaridze, and P. Boyle Cancer of the prostate: epidemiology and aetiology Br J Urol 59 1987 493 502 (Pubitemid 17075363)
    • (1987) British Journal of Urology , vol.59 , Issue.6 , pp. 493-502
    • Zaridze, D.G.1    Boyle, P.2
  • 14
    • 57149118824 scopus 로고    scopus 로고
    • Defining increased future risk for prostate cancer: Evidence from a population based screening cohort
    • F.H. Schröder, M.J. Roobol, G.L. Andriole, and N. Fleshner Defining increased future risk for prostate cancer: evidence from a population based screening cohort J Urol 181 2009 69 74
    • (2009) J Urol , vol.181 , pp. 69-74
    • Schröder, F.H.1    Roobol, M.J.2    Andriole, G.L.3    Fleshner, N.4
  • 15
    • 84855177156 scopus 로고    scopus 로고
    • Identifying and characterizing "escapes" - Men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam)
    • X. Zhu, P.J. van Leeuwen, M. Bul, C.H. Bangma, M.J. Roobol, and F.H. Schroder Identifying and characterizing "escapes" - men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam) Int J Cancer 129 2011 2847 2854
    • (2011) Int J Cancer , vol.129 , pp. 2847-2854
    • Zhu, X.1    Van Leeuwen, P.J.2    Bul, M.3    Bangma, C.H.4    Roobol, M.J.5    Schroder, F.H.6
  • 17
    • 0036190771 scopus 로고    scopus 로고
    • Role of family history and ethnicity on the mode and age of prostate cancer presentation
    • DOI 10.1002/pros.10051
    • M.P. Cotter, R.W. Gern, G.Y. Ho, R.Y. Chang, and R.D. Burk Role of family history and ethnicity on the mode and age of prostate cancer presentation Prostate 50 2002 216 221 (Pubitemid 34184660)
    • (2002) Prostate , vol.50 , Issue.4 , pp. 216-221
    • Cotter, M.P.1    Gern, R.W.2    Ho, G.Y.F.3    Chang, R.Y.4    Burk, R.D.5
  • 19
    • 0344874632 scopus 로고    scopus 로고
    • Populations at high risk for prostate cancer
    • DOI 10.1016/S0094-0143(03)00058-2
    • K. Hsieh, and P.C. Albertsen Populations at high risk for prostate cancer Urol Clin North Am 30 2003 669 676 (Pubitemid 37485184)
    • (2003) Urologic Clinics of North America , vol.30 , Issue.4 , pp. 669-676
    • Hsieh, K.1    Albertsen, P.C.2
  • 20
    • 0242268868 scopus 로고    scopus 로고
    • Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis
    • DOI 10.1002/ijc.11466
    • D.W. Bruner, D. Moore, A. Parlanti, J. Dorgan, and P. Engstrom Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis Int J Cancer 107 2003 797 803 (Pubitemid 37339734)
    • (2003) International Journal of Cancer , vol.107 , Issue.5 , pp. 797-803
    • Bruner, D.W.1    Moore, D.2    Parlanti, A.3    Dorgan, J.4    Engstrom, P.5
  • 21
    • 0037635390 scopus 로고    scopus 로고
    • A systematic review and meta-analysis of familial prostate cancer risk
    • DOI 10.1046/j.1464-410X.2003.04232.x
    • L.E. Johns, and R.S. Houlston A systematic review and meta-analysis of familial prostate cancer risk BJU Int 91 2003 789 794 (Pubitemid 36724060)
    • (2003) BJU International , vol.91 , Issue.9 , pp. 789-794
    • Johns, L.E.1    Houlston, R.S.2
  • 22
    • 77955309014 scopus 로고    scopus 로고
    • Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members
    • A. Brandt, J.L. Bermejo, J. Sundquist, and K. Hemminki Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members Eur Urol 58 2010 275 280
    • (2010) Eur Urol , vol.58 , pp. 275-280
    • Brandt, A.1    Bermejo, J.L.2    Sundquist, J.3    Hemminki, K.4
  • 23
    • 34648846905 scopus 로고    scopus 로고
    • The impact of obesity on prostate cancer
    • J.G. van Roermund, and J.A. Witjes The impact of obesity on prostate cancer World J Urol 25 2007 491 497
    • (2007) World J Urol , vol.25 , pp. 491-497
    • Van Roermund, J.G.1    Witjes, J.A.2
  • 24
    • 79960273058 scopus 로고    scopus 로고
    • The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series
    • D.M. Moreira, T. Anderson, and L. Gerber The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series Cancer Causes Control 22 2011 977 983
    • (2011) Cancer Causes Control , vol.22 , pp. 977-983
    • Moreira, D.M.1    Anderson, T.2    Gerber, L.3
  • 25
    • 52049112114 scopus 로고    scopus 로고
    • Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02
    • M.R. Smith, K. Bae, and J.A. Efstathiou Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02 J Clin Oncol 26 2008 4333 4339
    • (2008) J Clin Oncol , vol.26 , pp. 4333-4339
    • Smith, M.R.1    Bae, K.2    Efstathiou, J.A.3
  • 27
    • 80052103055 scopus 로고    scopus 로고
    • Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy
    • C. De Nunzio, S.J. Freedland, and R. Miano Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy Prostate 71 2011 1492 1498
    • (2011) Prostate , vol.71 , pp. 1492-1498
    • De Nunzio, C.1    Freedland, S.J.2    Miano, R.3
  • 28
    • 79953328519 scopus 로고    scopus 로고
    • Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer
    • J. Flanagan, P.K. Gray, and N. Hahn Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer Ann Oncol 22 2011 801 807
    • (2011) Ann Oncol , vol.22 , pp. 801-807
    • Flanagan, J.1    Gray, P.K.2    Hahn, N.3
  • 29
    • 68449101818 scopus 로고    scopus 로고
    • Components of the metabolic syndrome and risk of prostate cancer: The HUNT 2 cohort, Norway
    • R.M. Martin, L. Vatten, D. Gunnell, P. Romundstad, and T.I. Nilsen Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway Cancer Causes Control 20 2009 1181 1192
    • (2009) Cancer Causes Control , vol.20 , pp. 1181-1192
    • Martin, R.M.1    Vatten, L.2    Gunnell, D.3    Romundstad, P.4    Nilsen, T.I.5
  • 30
    • 79952075128 scopus 로고    scopus 로고
    • Comorbidity and mortality results from a randomized prostate cancer screening trial
    • E.D. Crawford, R. Grubb III, and A. Black Comorbidity and mortality results from a randomized prostate cancer screening trial J Clin Oncol 29 2010 355 361
    • (2010) J Clin Oncol , vol.29 , pp. 355-361
    • Crawford, E.D.1    Grubb Iii, R.2    Black, A.3
  • 31
    • 80053920100 scopus 로고    scopus 로고
    • Comorbidity and competing risks for mortality in men with prostate cancer
    • T.J. Daskivich, K. Chamie, and L. Kwan Comorbidity and competing risks for mortality in men with prostate cancer Cancer 117 2011 4642 4650
    • (2011) Cancer , vol.117 , pp. 4642-4650
    • Daskivich, T.J.1    Chamie, K.2    Kwan, L.3
  • 32
    • 79954428605 scopus 로고    scopus 로고
    • Impact of comorbidity on survival among men with localized prostate cancer
    • P.C. Albertsen, D.F. Moore, W. Shih, Y. Lin, H. Li, and G.L. Lu-Yao Impact of comorbidity on survival among men with localized prostate cancer J Clin Oncol 29 2011 1335 1341
    • (2011) J Clin Oncol , vol.29 , pp. 1335-1341
    • Albertsen, P.C.1    Moore, D.F.2    Shih, W.3    Lin, Y.4    Li, H.5    Lu-Yao, G.L.6
  • 33
    • 0034796225 scopus 로고    scopus 로고
    • Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop?
    • B. Djavan, V. Ravery, and A. Zlotta Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166 2001 1679 1683
    • (2001) J Urol , vol.166 , pp. 1679-1683
    • Djavan, B.1    Ravery, V.2    Zlotta, A.3
  • 35
    • 58849157659 scopus 로고    scopus 로고
    • Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy
    • J.L. Campos-Fernandes, L. Bastien, and N. Nicolaiew Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy Eur Urol 55 2009 600 609
    • (2009) Eur Urol , vol.55 , pp. 600-609
    • Campos-Fernandes, J.L.1    Bastien, L.2    Nicolaiew, N.3
  • 36
    • 0025849053 scopus 로고
    • Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
    • W.J. Catalona, D.S. Smith, and T.L. Ratliff Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N Engl J Med 324 1991 1156 1161
    • (1991) N Engl J Med , vol.324 , pp. 1156-1161
    • Catalona, W.J.1    Smith, D.S.2    Ratliff, T.L.3
  • 37
    • 0023233060 scopus 로고
    • Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
    • T.A. Stamey, N. Yang, A.R. Hay, J.E. McNeal, F.S. Freiha, and E. Redwine Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909 916 (Pubitemid 17147932)
    • (1987) New England Journal of Medicine , vol.317 , Issue.15 , pp. 909-916
    • Stamey, T.A.1    Yang, N.2    Hay, A.R.3
  • 38
    • 0030913316 scopus 로고    scopus 로고
    • Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: Enhancement of specificity with free PSA measurements
    • W.J. Catalona, D.S. Smith, and D.K. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements JAMA 277 1997 1452 1455 (Pubitemid 27208887)
    • (1997) Journal of the American Medical Association , vol.277 , Issue.18 , pp. 1452-1455
    • Catalona, W.J.1    Smith, D.S.2    Ornstein, D.K.3
  • 40
    • 0027972144 scopus 로고
    • 1-antichymotrypsin before diagnosis of prostate cancer
    • DOI 10.1016/S0140-6736(94)90405-7
    • U.H. Stenman, M. Hakama, P. Knekt, A. Aromaa, L. Teppo, and J. Leinonen Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer Lancet 344 1994 1594 1598 (Pubitemid 24365358)
    • (1994) Lancet , vol.344 , Issue.8937 , pp. 1594-1598
    • Stenman, U.-H.1    Hakama, M.2    Knekt, P.3    Aromaa, A.4    Teppo, L.5    Leinonen, J.6
  • 41
    • 0028801975 scopus 로고
    • A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
    • P.H. Gann, C.H. Hennekens, and M.J. Stampfer A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer JAMA 273 1995 289 294
    • (1995) JAMA , vol.273 , pp. 289-294
    • Gann, P.H.1    Hennekens, C.H.2    Stampfer, M.J.3
  • 42
    • 0034875454 scopus 로고    scopus 로고
    • Low levels of prostate-specific antigen predict long-term risk of prostate cancer: Results from the Baltimore Longitudinal Study of Aging
    • DOI 10.1016/S0090-4295(01)01304-8, PII S0090429501013048
    • J. Fang, E.J. Metter, P. Landis, D.W. Chan, C.H. Morrell, and H.B. Carter Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging Urology 58 2001 411 416 (Pubitemid 32816360)
    • (2001) Urology , vol.58 , Issue.3 , pp. 411-416
    • Fang, J.1    Metter E.Jeffrey2    Landis, P.3    Chan, D.W.4    Morrell, C.H.5    Carter H.Ballentine6
  • 43
    • 3242759906 scopus 로고    scopus 로고
    • Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study
    • DOI 10.1097/01.ju.0000132133.10470.bb
    • J.A. Antenor, M. Han, K.A. Roehl, R.B. Nadler, and W.J. Catalona Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study J Urol 172 2004 90 93 (Pubitemid 41615045)
    • (2004) Journal of Urology , vol.172 , Issue.1 , pp. 90-93
    • Antenor, J.A.V.1    Han, M.2    Roehl, K.A.3    Nadler, R.B.4    Catalona, W.J.5
  • 44
    • 31944436853 scopus 로고    scopus 로고
    • Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old
    • DOI 10.1016/j.urology.2005.08.040, PII S0090429505011970
    • S. Loeb, K.A. Roehl, J.A. Antenor, W.J. Catalona, B.K. Suarez, and R.B. Nadler Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old Urology 67 2006 316 320 (Pubitemid 43189848)
    • (2006) Urology , vol.67 , Issue.2 , pp. 316-320
    • Loeb, S.1    Roehl, K.A.2    Antenor, J.A.V.3    Catalona, W.J.4    Suarez, B.K.5    Nadler, R.B.6
  • 45
    • 79952133146 scopus 로고    scopus 로고
    • Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50
    • H. Lilja, A.M. Cronin, and A. Dahlin Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50 Cancer 117 2011 1210 1219
    • (2011) Cancer , vol.117 , pp. 1210-1219
    • Lilja, H.1    Cronin, A.M.2    Dahlin, A.3
  • 47
    • 41149091657 scopus 로고    scopus 로고
    • Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
    • D. Ulmert, A.M. Cronin, and T. Bjork Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study BMC Med 6 2008 6
    • (2008) BMC Med , vol.6 , pp. 6
    • Ulmert, D.1    Cronin, A.M.2    Bjork, T.3
  • 48
    • 77956811462 scopus 로고    scopus 로고
    • Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
    • A.J. Vickers, A.M. Cronin, and T. Bjork Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study BMJ 341 2010 c4521
    • (2010) BMJ , vol.341 , pp. 4521
    • Vickers, A.J.1    Cronin, A.M.2    Bjork, T.3
  • 49
    • 79952282237 scopus 로고    scopus 로고
    • Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam
    • M. Bul, P.J. van Leeuwen, X. Zhu, F.H. Schröder, and M.J. Roobol Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam Eur Urol 59 2011 498 505
    • (2011) Eur Urol , vol.59 , pp. 498-505
    • Bul, M.1    Van Leeuwen, P.J.2    Zhu, X.3    Schröder, F.H.4    Roobol, M.J.5
  • 50
    • 25144500004 scopus 로고    scopus 로고
    • Individualized screening interval for prostate cancer based on prostate-specific antigen level: Results of a prospective, randomized, population-based study
    • DOI 10.1001/archinte.165.16.1857
    • G. Aus, J.E. Damber, A. Khatami, H. Lilja, J. Stranne, and J. Hugosson Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study Arch Intern Med 165 2005 1857 1861 (Pubitemid 41352080)
    • (2005) Archives of Internal Medicine , vol.165 , Issue.16 , pp. 1857-1861
    • Aus, G.1    Damber, J.-E.2    Khatami, A.3    Lilja, H.4    Stranne, J.5    Hugosson, J.6
  • 51
    • 13844264517 scopus 로고    scopus 로고
    • Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam)
    • DOI 10.1016/j.urology.2004.09.046
    • M.J. Roobol, D.W. Roobol, and F.H. Schröder Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/ml or less in a population-based screening setting? (ERSPC, section Rotterdam) Urology 65 2005 343 346 (Pubitemid 40248025)
    • (2005) Urology , vol.65 , Issue.2 , pp. 343-346
    • Roobol, M.J.1    Roobol, D.W.2    Schroder, F.H.3
  • 52
    • 78049479383 scopus 로고    scopus 로고
    • Balancing the harms and benefits of early detection of prostate cancer
    • P.J. van Leeuwen, D. Connolly, and T.L. Tammela Balancing the harms and benefits of early detection of prostate cancer Cancer 116 2010 4857 4865
    • (2010) Cancer , vol.116 , pp. 4857-4865
    • Van Leeuwen, P.J.1    Connolly, D.2    Tammela, T.L.3
  • 54
    • 64349085837 scopus 로고    scopus 로고
    • Risk of developing prostate cancer in the future: Overview of prognostic biomarkers
    • N.E. Fleshner, and N. Lawrentschuk Risk of developing prostate cancer in the future: overview of prognostic biomarkers Urology 73 2009 S21 S27
    • (2009) Urology , vol.73
    • Fleshner, N.E.1    Lawrentschuk, N.2
  • 56
    • 37349005496 scopus 로고    scopus 로고
    • Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only
    • DOI 10.1016/j.urology.2007.07.019, PII S009042950701833X
    • O.T. Okotie, K.A. Roehl, M. Han, S. Loeb, S.N. Gashti, and W.J. Catalona Characteristics of prostate cancer detected by digital rectal examination only Urology 70 2007 1117 1120 (Pubitemid 350297358)
    • (2007) Urology , vol.70 , Issue.6 , pp. 1117-1120
    • Okotie, O.T.1    Roehl, K.A.2    Han, M.3    Loeb, S.4    Gashti, S.N.5    Catalona, W.J.6
  • 60
    • 35648943184 scopus 로고    scopus 로고
    • High Yield of Saturation Prostate Biopsy for Patients with Previous Negative Biopsies and Small Prostates
    • DOI 10.1016/j.urology.2007.05.017, PII S0090429507006012
    • K.P. Sajadi, T. Kim, M.K. Terris, J.A. Brown, and R.W. Lewis High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates Urology 70 2007 691 695 (Pubitemid 350030213)
    • (2007) Urology , vol.70 , Issue.4 , pp. 691-695
    • Sajadi, K.P.1    Kim, T.2    Terris, M.K.3    Brown, J.A.4    Lewis, R.W.5
  • 61
    • 84856380113 scopus 로고    scopus 로고
    • Prediction of prostate cancer risk: The role of prostate volume and digital rectal examination in the ERSPC risk calculators
    • M.J. Roobol, H.A. Van Vugt, and S. Loeb Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators Eur Urol 61 2012 577 583
    • (2012) Eur Urol , vol.61 , pp. 577-583
    • Roobol, M.J.1    Van Vugt, H.A.2    Loeb, S.3
  • 62
    • 0026755373 scopus 로고
    • Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease
    • H.B. Carter, C.H. Morrell, and J.D. Pearson Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease Cancer Res 52 1992 3323 3328
    • (1992) Cancer Res , vol.52 , pp. 3323-3328
    • Carter, H.B.1    Morrell, C.H.2    Pearson, J.D.3
  • 63
    • 0028787237 scopus 로고
    • Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity
    • H.B. Carter, J.D. Pearson, and Z. Waclawiw Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity Urology 45 1995 591 596
    • (1995) Urology , vol.45 , pp. 591-596
    • Carter, H.B.1    Pearson, J.D.2    Waclawiw, Z.3
  • 64
    • 54449098163 scopus 로고    scopus 로고
    • PSA velocity is associated with Gleason score in radical prostatectomy specimen: Marker for prostate cancer aggressiveness
    • discussion 1120
    • S. Loeb, D.E. Sutherland, A.V. D'Amico, K.A. Roehl, and W.J. Catalona PSA velocity is associated with Gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness Urology 72 2008 1116 1120 discussion 1120
    • (2008) Urology , vol.72 , pp. 1116-1120
    • Loeb, S.1    Sutherland, D.E.2    D'Amico, A.V.3    Roehl, K.A.4    Catalona, W.J.5
  • 65
    • 71249150273 scopus 로고    scopus 로고
    • Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?
    • S. Loeb, K.A. Roehl, B.T. Helfand, D. Kan, and W.J. Catalona Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? J Urol 183 2010 112 116
    • (2010) J Urol , vol.183 , pp. 112-116
    • Loeb, S.1    Roehl, K.A.2    Helfand, B.T.3    Kan, D.4    Catalona, W.J.5
  • 67
    • 40849140583 scopus 로고    scopus 로고
    • Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer
    • J.J. Meeks, C.S. Thaxton, S. Loeb, K.A. Roehl, B.T. Helfand, and W.J. Catalona Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer J Urol 179 2008 1340 1343
    • (2008) J Urol , vol.179 , pp. 1340-1343
    • Meeks, J.J.1    Thaxton, C.S.2    Loeb, S.3    Roehl, K.A.4    Helfand, B.T.5    Catalona, W.J.6
  • 68
    • 34250795026 scopus 로고    scopus 로고
    • Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors
    • DOI 10.1002/cncr.22737
    • A.V. D'Amico, M.H. Chen, W.J. Catalona, L. Sun, K.A. Roehl, and J.W. Moul Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors Cancer 110 2007 56 61 (Pubitemid 46986418)
    • (2007) Cancer , vol.110 , Issue.1 , pp. 56-61
    • D'Amico, A.V.1    Chen, M.-H.2    Catalona, W.J.3    Sun, L.4    Roehl, K.A.5    Moul, J.W.6
  • 69
    • 3042727071 scopus 로고    scopus 로고
    • Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy
    • A.V. D'Amico, M.H. Chen, K.A. Roehl, and W.J. Catalona Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 351 2004 125 135
    • (2004) N Engl J Med , vol.351 , pp. 125-135
    • D'Amico, A.V.1    Chen, M.H.2    Roehl, K.A.3    Catalona, W.J.4
  • 70
    • 39749180009 scopus 로고    scopus 로고
    • Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population
    • DOI 10.1200/JCO.2007.13.1490
    • D. Ulmert, A.M. Serio, and M.F. O'Brien Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population J Clin Oncol 26 2008 835 841 (Pubitemid 351398073)
    • (2008) Journal of Clinical Oncology , vol.26 , Issue.6 , pp. 835-841
    • Ulmert, D.1    Serio, A.M.2    O'Brien, M.F.3    Becker, C.4    Eastham, J.A.5    Scardino, P.T.6    Bjork, T.7    Berglund, G.8    Vickers, A.J.9    Lilja, H.10
  • 72
    • 1242296763 scopus 로고    scopus 로고
    • Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: Results of second screening round of ERSPC (ROTTERDAM)
    • DOI 10.1016/j.urology.2003.09.083
    • M.J. Roobol, R. Kranse, H.J. de Koning, and F.H. Schroder Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM) Urology 63 2004 309 313 discussion 313-5 (Pubitemid 38234425)
    • (2004) Urology , vol.63 , Issue.2 , pp. 309-313
    • Roobol, M.J.1    Kranse, R.2    De Koning, H.J.3    Schroder, F.H.4
  • 73
    • 32944463469 scopus 로고    scopus 로고
    • Does PSA velocity predict prostate cancer in pre-screened populations?
    • DOI 10.1016/j.eururo.2005.12.026, PII S0302283805008419
    • F.H. Schröder, M.J. Roobol, T.H. van der Kwast, R. Kranse, and C.H. Bangma Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 49 2006 460 465 discussion 465 (Pubitemid 43259552)
    • (2006) European Urology , vol.49 , Issue.3 , pp. 460-465
    • Schroder, F.H.1    Roobol, M.J.2    Van Der Kwast, T.H.3    Kranse, R.4    Bangma, C.H.5
  • 74
    • 70349295163 scopus 로고    scopus 로고
    • Prostate-specific antigen velocity for early detection of prostate cancer: Result from a large, representative, population-based cohort
    • A.J. Vickers, T. Wolters, and C.J. Savage Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort Eur Urol 56 2009 753 760
    • (2009) Eur Urol , vol.56 , pp. 753-760
    • Vickers, A.J.1    Wolters, T.2    Savage, C.J.3
  • 75
    • 79952833310 scopus 로고    scopus 로고
    • An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection
    • A.J. Vickers, C. Till, C.M. Tangen, H. Lilja, and I.M. Thompson An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection J Natl Cancer Inst 103 2011 462 469
    • (2011) J Natl Cancer Inst , vol.103 , pp. 462-469
    • Vickers, A.J.1    Till, C.2    Tangen, C.M.3    Lilja, H.4    Thompson, I.M.5
  • 76
    • 78049457613 scopus 로고    scopus 로고
    • On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer
    • C.H. Bangma, R.H. van Schaik, B.G. Blijenberg, M.J. Roobol, H. Lilja, and U.H. Stenman On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer Eur J Cancer 46 2010 3109 3119
    • (2010) Eur J Cancer , vol.46 , pp. 3109-3119
    • Bangma, C.H.1    Van Schaik, R.H.2    Blijenberg, B.G.3    Roobol, M.J.4    Lilja, H.5    Stenman, U.H.6
  • 77
    • 79953777963 scopus 로고    scopus 로고
    • A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range
    • W.J. Catalona, A.W. Partin, and M.G. Sanda A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 2011 1650 1655
    • (2011) J Urol , vol.185 , pp. 1650-1655
    • Catalona, W.J.1    Partin, A.W.2    Sanda, M.G.3
  • 78
    • 79959554692 scopus 로고    scopus 로고
    • Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting
    • G. Guazzoni, L. Nava, and M. Lazzeri Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA Between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting Eur Urol 60 2011 214 222
    • (2011) Eur Urol , vol.60 , pp. 214-222
    • Guazzoni, G.1    Nava, L.2    Lazzeri, M.3
  • 79
    • 77949277570 scopus 로고    scopus 로고
    • [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study
    • B.V. Le, C.R. Griffin, and S. Loeb [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 183 2010 1355 1359
    • (2010) J Urol , vol.183 , pp. 1355-1359
    • Le, B.V.1    Griffin, C.R.2    Loeb, S.3
  • 80
    • 77951621115 scopus 로고    scopus 로고
    • Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection
    • F.H. Jansen, R.H.N. van Schaik, and J. Kurstjens Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921 927
    • (2010) Eur Urol , vol.57 , pp. 921-927
    • Jansen, F.H.1    Van Schaik, R.H.N.2    Kurstjens, J.3
  • 81
    • 0035018273 scopus 로고    scopus 로고
    • The new human tissue kallikrein gene family: Structure, function, and association to disease
    • DOI 10.1210/er.22.2.184
    • G.M. Yousef, and E.P. Diamandis The new human tissue kallikrein gene family: structure, function, and association to disease Endocr Rev 22 2001 184 204 (Pubitemid 32458158)
    • (2001) Endocrine Reviews , vol.22 , Issue.2 , pp. 184-204
    • Yousef, G.M.1    Diamandis, E.P.2
  • 82
    • 0034185675 scopus 로고    scopus 로고
    • Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater
    • C. Becker, T. Piironen, K. Pettersson, J. Hugosson, and H. Lilja Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater Urology 55 2000 694 699
    • (2000) Urology , vol.55 , pp. 694-699
    • Becker, C.1    Piironen, T.2    Pettersson, K.3    Hugosson, J.4    Lilja, H.5
  • 85
    • 77953688557 scopus 로고    scopus 로고
    • Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication
    • A. Vickers, A. Cronin, and M. Roobol Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication J Clin Oncol 28 2010 2493 2498
    • (2010) J Clin Oncol , vol.28 , pp. 2493-2498
    • Vickers, A.1    Cronin, A.2    Roobol, M.3
  • 86
    • 48249152185 scopus 로고    scopus 로고
    • A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: Data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
    • A.J. Vickers, A.M. Cronin, and G. Aus A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden BMC Med 6 2008 19
    • (2008) BMC Med , vol.6 , pp. 19
    • Vickers, A.J.1    Cronin, A.M.2    Aus, G.3
  • 87
    • 79951626849 scopus 로고    scopus 로고
    • A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening
    • A.J. Vickers, A. Gupta, and C.J. Savage A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening Cancer Epidemiol Biomarkers Prev 20 2011 255 261
    • (2011) Cancer Epidemiol Biomarkers Prev , vol.20 , pp. 255-261
    • Vickers, A.J.1    Gupta, A.2    Savage, C.J.3
  • 90
    • 79955056992 scopus 로고    scopus 로고
    • Contemporary role of prostate cancer gene 3 in the management of prostate cancer
    • M.J. Roobol Contemporary role of prostate cancer gene 3 in the management of prostate cancer Curr Opin Urol 21 2011 225 229
    • (2011) Curr Opin Urol , vol.21 , pp. 225-229
    • Roobol, M.J.1
  • 91
    • 77956535473 scopus 로고    scopus 로고
    • Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: Exploring the value of PCA3 for a first-line diagnostic test
    • M.J. Roobol, F.H. Schröder, and P. van Leeuwen Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 2010 475 481
    • (2010) Eur Urol , vol.58 , pp. 475-481
    • Roobol, M.J.1    Schröder, F.H.2    Van Leeuwen, P.3
  • 92
    • 54049139306 scopus 로고    scopus 로고
    • Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium
    • Z. Kote-Jarai, D.F. Easton, and J.L. Stanford Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium Cancer Epidemiol Biomarkers Prev 17 2008 2052 2061
    • (2008) Cancer Epidemiol Biomarkers Prev , vol.17 , pp. 2052-2061
    • Kote-Jarai, Z.1    Easton, D.F.2    Stanford, J.L.3
  • 93
    • 80051813565 scopus 로고    scopus 로고
    • A risk prediction algorithm based on family history and common genetic variants: Application to prostate cancer with potential clinical impact
    • R.J. Macinnis, A.C. Antoniou, and R.A. Eeles A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact Genet Epidemiol 35 2011 549 556
    • (2011) Genet Epidemiol , vol.35 , pp. 549-556
    • MacInnis, R.J.1    Antoniou, A.C.2    Eeles, R.A.3
  • 94
    • 50449098019 scopus 로고    scopus 로고
    • Variation in KLK genes, prostate-specific antigen and risk of prostate cancer
    • author reply 1035-6
    • J. Ahn, S.I. Berndt, and S. Wacholder Variation in KLK genes, prostate-specific antigen and risk of prostate cancer Nat Genet 40 2008 1032 1034 author reply 1035-6
    • (2008) Nat Genet , vol.40 , pp. 1032-1034
    • Ahn, J.1    Berndt, S.I.2    Wacholder, S.3
  • 95
    • 77952026425 scopus 로고    scopus 로고
    • Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: Kallikreins and prostate cancer
    • R.J. Klein, C. Hallden, and A.M. Cronin Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer Cancer Prev Res (Phila) 3 2010 611 619
    • (2010) Cancer Prev Res (Phila) , vol.3 , pp. 611-619
    • Klein, R.J.1    Hallden, C.2    Cronin, A.M.3
  • 96
    • 79957520906 scopus 로고    scopus 로고
    • Tumour markers in prostate cancer III: Biomarkers in urine
    • M.J. Roobol, A. Haese, and A. Bjartell Tumour markers in prostate cancer III: biomarkers in urine Acta Oncol 50 Suppl 1 2011 85 89
    • (2011) Acta Oncol , vol.50 , Issue.SUPPL. 1 , pp. 85-89
    • Roobol, M.J.1    Haese, A.2    Bjartell, A.3
  • 97
    • 45849109563 scopus 로고    scopus 로고
    • The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: A systematic review
    • F. Schröder, and M.W. Kattan The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review Eur Urol 54 2008 274 290
    • (2008) Eur Urol , vol.54 , pp. 274-290
    • Schröder, F.1    Kattan, M.W.2
  • 98
    • 71849102519 scopus 로고    scopus 로고
    • Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection
    • S.J. Eyre, D.P. Ankerst, and J.T. Wei Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection J Urol 182 2009 2653 2658
    • (2009) J Urol , vol.182 , pp. 2653-2658
    • Eyre, S.J.1    Ankerst, D.P.2    Wei, J.T.3
  • 99
    • 60449108184 scopus 로고    scopus 로고
    • Predicting the outcome of prostate biopsy: Comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone
    • D.J. Hernandez, M. Han, and E.B. Humphreys Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone BJU Int 103 2009 609 614
    • (2009) BJU Int , vol.103 , pp. 609-614
    • Hernandez, D.J.1    Han, M.2    Humphreys, E.B.3
  • 100
    • 78651268239 scopus 로고    scopus 로고
    • The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients
    • T.C. Ngo, B.B. Turnbull, P.W. Lavori, and J.C. Presti Jr. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients J Urol 185 2011 483 487
    • (2011) J Urol , vol.185 , pp. 483-487
    • Ngo, T.C.1    Turnbull, B.B.2    Lavori, P.W.3    Presti, Jr.J.C.4
  • 101
    • 73749088254 scopus 로고    scopus 로고
    • Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy
    • C.T. Nguyen, C. Yu, A. Moussa, M.W. Kattan, and J.S. Jones Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy J Urol 183 2010 529 533
    • (2010) J Urol , vol.183 , pp. 529-533
    • Nguyen, C.T.1    Yu, C.2    Moussa, A.3    Kattan, M.W.4    Jones, J.S.5
  • 103
    • 80051646902 scopus 로고    scopus 로고
    • Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators
    • R.K. Nam, M.W. Kattan, and J.L. Chin Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators J Clin Oncol 29 2011 2959 2964
    • (2011) J Clin Oncol , vol.29 , pp. 2959-2964
    • Nam, R.K.1    Kattan, M.W.2    Chin, J.L.3
  • 104
    • 55249102250 scopus 로고    scopus 로고
    • A graphical device to represent the outcomes of a logistic regression analysis
    • R. Kranse, M. Roobol, and F.H. Schröder A graphical device to represent the outcomes of a logistic regression analysis Prostate 68 2008 1674 1680
    • (2008) Prostate , vol.68 , pp. 1674-1680
    • Kranse, R.1    Roobol, M.2    Schröder, F.H.3
  • 105
    • 78650255605 scopus 로고    scopus 로고
    • Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators: A performance comparison in a contemporary screened cohort
    • V. Cavadas, L. Osório, F. Sabell, F. Teves, F. Branco, and M. Silva-Ramos Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators: a performance comparison in a contemporary screened cohort Eur Urol 58 2010 551 558
    • (2010) Eur Urol , vol.58 , pp. 551-558
    • Cavadas, V.1    Osório, L.2    Sabell, F.3    Teves, F.4    Branco, F.5    Silva-Ramos, M.6
  • 106
    • 79956368759 scopus 로고    scopus 로고
    • Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction
    • M. Oliveira, V. Marques, A.P. Carvalho, and A. Santos Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction BJU Int 107 2011 1780 1783
    • (2011) BJU Int , vol.107 , pp. 1780-1783
    • Oliveira, M.1    Marques, V.2    Carvalho, A.P.3    Santos, A.4
  • 107
    • 80054016806 scopus 로고    scopus 로고
    • Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort
    • G. Trottier, M.J. Roobol, and N. Lawrentschuk Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort BJU Int 108 2011 E237 E244
    • (2011) BJU Int , vol.108
    • Trottier, G.1    Roobol, M.J.2    Lawrentschuk, N.3
  • 108
    • 79952985149 scopus 로고    scopus 로고
    • Prediction of prostate cancer in unscreened men: External validation of a risk calculator
    • H.A. van Vugt, M.J. Roobol, and R. Kranse Prediction of prostate cancer in unscreened men: external validation of a risk calculator Eur J Cancer 47 2011 903 909
    • (2011) Eur J Cancer , vol.47 , pp. 903-909
    • Van Vugt, H.A.1    Roobol, M.J.2    Kranse, R.3
  • 110
    • 33750905259 scopus 로고    scopus 로고
    • Decision curve analysis: A novel method for evaluating prediction models
    • DOI 10.1177/0272989X06295361
    • A.J. Vickers, and E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Medical Decision Making 26 2006 565 574 (Pubitemid 44728772)
    • (2006) Medical Decision Making , vol.26 , Issue.6 , pp. 565-574
    • Vickers, A.J.1    Elkin, E.B.2
  • 111
    • 78649362120 scopus 로고    scopus 로고
    • EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease
    • A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
    • (2011) Eur Urol , vol.59 , pp. 61-71
    • Heidenreich, A.1    Bellmunt, J.2    Bolla, M.3
  • 113
    • 77949363162 scopus 로고    scopus 로고
    • American Cancer Society guideline for the early detection of prostate cancer: Update 2010
    • A.M. Wolf, R.C. Wender, and R.B. Etzioni American Cancer Society guideline for the early detection of prostate cancer: update 2010 CA Cancer J Clin 60 2010 70 98
    • (2010) CA Cancer J Clin , vol.60 , pp. 70-98
    • Wolf, A.M.1    Wender, R.C.2    Etzioni, R.B.3
  • 114
    • 77649099098 scopus 로고    scopus 로고
    • NCCN clinical practice guidelines in oncology: Prostate cancer early detection
    • M.H Kawachi, R.R. Bahnson, and M. Barry NCCN clinical practice guidelines in oncology: prostate cancer early detection J Natl Compr Canc Netw 8 2010 240 262
    • (2010) J Natl Compr Canc Netw , vol.8 , pp. 240-262
    • Kawachi, M.H.1    Bahnson, R.R.2    Barry, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.